ROANOKE, Va., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated Company earnings of $4.9 million, or $0.47 per share, for the first quarter ended December 31, 2025, compared to $5.3 million, or $0.51 per share, for the first quarter ended December 31, 2024. The decrease reflected flat margins and higher costs for personnel, IT, property taxes and depreciation, which were partially offset by lower interest expense. The Company filed a rate case in early December seek ...

The Nasdaq-listed company has recurring losses and no revenue. ...

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Monday.Shares of Revolution Medicines Inc (NASDAQ:RVMD) dipped 26.1% to $87.02 in pre-market trading.The Wall Street Journal Reported that Merck (NYSE:MRK) is no longer in talks to acquire Revolution Medicines.Revolution Medicines shares dipped 26.1% to $87.02 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Erasca Inc (NASDAQ:ERAS) fell 11.5% to $8.82 in pre-market trading. Erasca anno ...

| 代码 | 名称 | 最新价 | 涨跌幅 √ | 涨跌额 | 成交额 | | --- | --- | --- | --- | --- | --- | | RGC | 脑再生科技 | 30.770 | 40.44% | +8.860 | 3724.75万 | | BNR | 燃石医学 | 41.060 | 32.20% | +10.000 | 408.11万 | | FEDU | 四季教育 | 10.000 | 30.21% | +2.320 | 368.78万 | | JEM | 707 Cayman Holdings | 0.2505 | 26.58% | +0.0526 | 506.29万 | | ADAG | 天演药业 | 2.030 | 20.12% | +0.340 | 115.83万 | 中概股收盘涨幅居前的个股为：脑再生科技涨40.44%，燃石医学涨32.2%，四季教育涨30.21%，707 Cayman Holdings涨26.58%，天演药业涨20.12%。(格隆汇) ...

Group 1 - The core point of the article highlights the significant decline in the stock prices of several Chinese concept stocks, with TJGC Group experiencing the largest drop at 27.78% [1] - TJGC Group's latest price is reported at 1.040, with a decrease of 0.400 and a trading volume of 255,500 [1] - Baojia International saw a decline of 19.06%, with its latest price at 4.500, down by 1.060, and a trading volume of 956,300 [1] - Brain Rejuvenation Technology's stock fell by 14.53%, with a current price of 30.060, down by 5.110, and a trading volume of 14,102,600 [1] - Ridgetech's stock decreased by 14.46%, with a latest price of 2.360, down by 0.399, and a trading volume of 32,900 [1] - Dongfang Culture experienced a decline of 14.41%, with its latest price at 0.0101, down by 0.0017, and a trading volume of 4,632,400 [1]

Group 1 - The core point of the article highlights significant declines in the stock prices of several Chinese concept stocks, with notable drops in their trading volumes and market performance [1] Group 2 - Ming Teng International (MTEN) experienced a drastic decline of 43.15%, closing at 0.603 with a trading volume of 7.2959 million [1] - Su Xuan Tang (SXTC) saw a drop of 37.5%, closing at 1.250 with a trading volume of 416 million [1] - Brain Rejuvenation Technology (RGC) fell by 21.67%, closing at 41.420 with a trading volume of 166 million [1] - Pai Ming Chip City (IZM) decreased by 17.65%, closing at 2.100 with a trading volume of 56.11 million [1] - Star Map International (YIBO) dropped by 15.63%, closing at 0.8100 with a trading volume of 45.9 thousand [1]

Core Insights - Brain-computer interface (BCI) technology is rapidly moving towards commercialization and industrialization due to technological breakthroughs, policy support, and global industry resonance [1] Company Developments - Neuralink, a brain-machine interface company founded by Elon Musk, plans to begin large-scale production of its brain interface devices in 2026 [1] - The company is focusing on streamlining and automating surgical procedures, with a significant breakthrough allowing electrode wires to penetrate the dura mater without needing to remove it [1] Industry Trends - The Chinese Ministry of Industry and Information Technology, along with eight other departments, issued a directive on January 7 to accelerate the industrialization and commercialization of new terminals like brain-computer interfaces [1] - The convergence of technological advancements and supportive policies is propelling the BCI sector from a cutting-edge scientific concept to a critical leap towards commercial viability [1]

Group 1 - The core viewpoint of the news is that Neural Regeneration Technology (RGC.US) has seen a significant stock price increase, rising 16.3% in pre-market trading and a total of 157% over the past three days, driven by Elon Musk's recent production forecast, which has catalyzed a surge in the brain-computer interface sector [1] - RGC's relationship with brain-computer interfaces can be understood as an upstream and downstream connection in medicine, where "repairing hardware" relates to "establishing connections" [1] - According to a report from Changjiang Securities, the brain-computer interface industry in China is experiencing rapid advancements, and with policy support, it is expected to enter a period of development opportunities, accelerating the transition from industrial research to commercialization [1] Group 2 - As of January 7, the closing price of RGC was $52.880, reflecting a 60.10% increase, while the pre-market price on January 8 was $61.500, up 16.30% [2] - The stock has shown significant volatility, with a trading range of 59.37% and a turnover rate of 17.48% [2] - The total market capitalization of RGC is approximately $26.149 billion, with a total share count of 494 million [2]

Core Viewpoint - Chinese concept stocks experienced significant gains, with notable increases in share prices for several companies, indicating a positive market sentiment towards these stocks [1] Group 1: Stock Performance - Brain Rejuvenation Technology (RGC) saw a remarkable increase of 60.10%, closing at 52.880 with a trading volume of 146 million [1] - Ming Teng International (MTEN) rose by 21.84%, closing at 1.0600 with a trading volume of 970,000 [1] - Interstellar Fashion (STFS) increased by 21.42%, closing at 0.1230 with a trading volume of 502,500 [1] - Su Xuan Tang (SXTC) experienced an 18.34% rise, closing at 2.000 with a trading volume of 214,200 [1] - Triller Group (ILLR) gained 17.65%, closing at 0.0300 with a trading volume of 14,200 [1]

Market Overview - U.S. stocks showed mixed performance, with the Dow Jones index declining approximately 0.2% on Wednesday [1] Company Highlights - Monte Rosa Therapeutics Inc (NASDAQ:GLUE) experienced a significant increase in share price, rising 45.2% to $23.25 after announcing interim data from a Phase 1 clinical study for MRT-8102 [1] - Ventyx Biosciences Inc (NASDAQ:VTYX) shares surged 37.5% to $13.82 following reports of advanced acquisition talks with Eli Lilly & Co. (NYSE:LLY) for over $1 billion [2] - Neumora Therapeutics Inc (NASDAQ:NMRA) saw a rise of 24.7% to $2.27 [2] - Regencell Bioscience Holdings Ltd (NASDAQ:RGC) increased by 21.1% to $40.00 [2] - Erasca Inc (NASDAQ:ERAS) rose 17.1% to $4.25, with Piper Sandler initiating coverage with an Overweight rating and a price target of $5 [2] - Anywhere Real Estate Inc (NYSE:HOUS) gained 15.6% to $16.71 [2] - AXT Inc (NASDAQ:AXTI) increased by 13.8% to $22.96 [2] - Immuneering Corp (NASDAQ:IMRX) rose 13.1% to $7.60 [2] - Compass Therapeutics Inc. (NASDAQ:CMPX) gained 13.1% to $5.56 [2] - MBX Biosciences Inc (NASDAQ:MBX) rose 11.2% to $31.90 [2] - Rezolve AI PLC (NASDAQ:RZLV) increased by 10.8% to $3.36 [2] - United Microelectronics Corp (NYSE:UMC) gained 10.4% to $8.96 after reporting sales growth for December and the full year [2] - PBF Energy Inc (NYSE:PBF) rose 9.2% to $29.73 [2] - Navan Inc (NASDAQ:NAVN) increased by 8.3% to $18.42 [2] - Ascentage Pharma Group International (NASDAQ:AAPG) gained 8.3% to $28.17 after announcing IND clearance for BTK Degrader APG-3288 by the U.S. FDA [2] - Intel Corp (NASDAQ:INTC) rose 6.4% to $42.60 as the company is enhancing its gaming strategy by developing a new chip for handheld gaming devices [2]